12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pomalyst pomalidomide regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA for Celgene's pomalidomide to treat patients with relapsed and refractory multiple myeloma (MM) who have received >=2 prior therapies, including both Velcade bortezomib and Celgene's Revlimid lenalidomide, and whose disease progressed while on their last therapy. The committee...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >